## 1 Title:

- 2 Hypothalamic structure and function in Alzheimer's disease and Lewy-body dementia: a
- 3 systematic review and meta-analysis

## 4 Authors:

- 5 Axel AS Laurell<sup>1,2,\*</sup>, Sita N Shah<sup>1,2</sup>, Masoud Rahmati<sup>3,4,5</sup>, John T O'Brien<sup>1,2</sup>, Benjamin R
- 6 Underwood<sup>1,2</sup>

## 7 Affiliations:

- 8 <sup>1</sup>Department of Psychiatry, University of Cambridge School of Clinical Medicine, Level E4,
- 9 Addenbrooke's Hospital, Hills Road, Cambridge, CB2 2QQ, United Kingdom.
- 10 <sup>2</sup>Cambridgeshire and Peterborough NHS Foundation Trust, Windsor Unit, Fulbourn Hospital,
- 11 Cambridge CB21 5EF
- 12 <sup>3</sup>CEReSS-Health Service Research and Quality of Life Center, Aix-Marseille University,
- 13 Marseille, France
- <sup>4</sup> Department of Physical Education and Sport Sciences, Faculty of Literature and Human
- 15 Sciences, Lorestan University, Khoramabad, Iran,
- <sup>5</sup> Department of Physical Education and Sport Sciences, Faculty of Literature and
- 17 Humanities, Vali-E-Asr University of Rafsanjan, Rafsanjan, Iran
- 18 \*Corresponding author:
- 19 al2087@cam.ac.uk

20

#### 21 Abstract

## 22 Background

- 23 Changes to sleep, weight, and endocrine function are common in Alzheimer's disease (AD)
- 24 and Lewy-body dementia (LBD). The cause of these is not known, but they may be related
- 25 to hypothalamic neurodegeneration.

## 26 Methods

- 27 We performed a systematic search of MEDLINE and EMBASE of studies using structural
- 28 magnetic resonance imaging to examine hypothalamic volume in people with AD or LBD.
- 29 The Newcastle-Ottawa scale was used to assess the risk of bias. A random-effects meta-
- 30 analysis was conducted using the standardised mean difference (SMD) in hypothalamic
- 31 volume as the effect measure, and a narrative synthesis was used to examine the
- 32 relationship between hypothalamic volume and sleep, eating, and endocrine function.

### 33 <u>Results</u>

- 34 We identified 6542 articles which resulted in 12 included studies, most which had a low to
- 35 moderate risk of bias. The meta-analysis included 454 people with mild-moderate AD (Mini-
- 36 Mental State (MMSE) range: 19.2-26.1) and 715 controls. We found that people with AD had
- a significantly smaller hypothalamus (pooled SMD: -0.49, t=-3.47, p=0.018, 95%CI: -0.86 to -
- 0.13). There was significant heterogeneity of a moderate degree (Tau<sup>2</sup>=0.0665,
- 39 95%Cl:0.005-0.8090; l<sup>2</sup>=67%, 95%Cl:21.5%-86.1%; Q=15.16, p<0.01), but no evidence of
- 40 publication bias. Only one study examined people with LBD, finding qualitative evidence of
- 41 lower hypothalamic volume compared to controls. Hypothalamic volume loss in AD was
- 42 more marked in men and may be associated with plasma levels of sex hormones and
- 43 decreased bone mineral density.

## 44 Conclusion

- 45 Reduced hypothalamic volume is seen early in AD and LBD and this may influence
- 46 endocrine function. A better understanding of hypothalamic degeneration in dementia may
- 47 help elucidate how pathology relates to symptoms in AD and LBD and reveal new targets for
- 48 intervention.

#### 49 **1.0 Introduction**

50 Alzheimer's disease (AD) and Lewy-body dementia (LBD), consisting of Dementia with Lewy 51 Bodies (DLB) and Parkinson's disease dementia (PDD), are two of the most common 52 causes of dementia (Goodman et al., 2017). In addition to the well-described cognitive 53 impairment associated with these illnesses, many people with AD and LBD develop other 54 symptoms including sleep disturbances (Koren et al., 2023), loss of appetite (Soysal et al., 55 2021), endocrine (Popp et al., 2015) and metabolic dysfunction (Xie et al., 2023). The 56 causes of these are poorly understood, but may be related to neurodegenerative changes in 57 specific brain regions that are involved in the control of these physiological processes. The 58 hypothalamus is a small grey matter structure which consists of more than 12 different nuclei 59 that are responsible for regulating a range of homeostatic, metabolic and autonomic 60 functions, including appetite and the 24-hour circadian rhythm (Ishii and Iadecola, 2015). 61 The hypothalamus is also the main regulator of many of the body's endocrine processes via 62 pathways such as the hypothalamic-pituitary-adrenal (HPA) axis, the hypothalamic-pituitary-63 gonadal (HPG) axis, the hypothalamic-pituitary-thyroid axis and the hypothalamic-pituitary-64 somatotropic axis. Changes in plasma levels of glucocorticoids (Huang et al., 2009), sex 65 hormones (Livingston et al., 2024), thyroid hormones (Tang et al., 2021), and somatotropic 66 hormones (Westwood et al., 2014) are associated with increased risk of developing 67 dementia and metabolic conditions such as osteoporosis, indicating that hypothalamic 68 signalling pathways may be involved (Niwczyk et al., 2023). 69 Although, neuropathological studies have established that the hypothalamus is affected by 70 LBD (Braak et al., 2003) and AD pathology (Braak and Braak, 1991), it is not clear if this is

an early or late feature of these conditions or whether there is a functional impact of

72 neurodegeneration in this structure. These are important questions as it is possible that

73 hypothalamic neuronal loss could drive global pathology, for example through changes in

sleep, and any impact on the endocrine system could be related to AD symptomatology. The

75 hypothalamus is a promising drug target due to its diverse and well understood receptor

profile so understanding its role in disease might quickly translate into treatment (Romanovet al. 2017).

78 One challenge of studying the hypothalamus *in vivo* using magnetic resonance imaging

79 (MRI) is its small size and poor tissue contrast, and traditional methods of manual

80 segmentation are time-consuming and requires expert knowledge of neuroanatomy.

81 Recently, several automatic segmentation pipelines have been developed which allows the

82 hypothalamus to be segmented into subregions (Billot et al., 2020; Chang et al., 2022). This

83 allows the hypothalamic volume to be evaluated in larger cohort studies to assess whether

- 84 the hypothalamus is affected early in dementia. It also makes it possible to test the
- 85 hypothesis that volumetric changes in specific hypothalamic subunits are associated with
- 86 specific signs and symptoms. The primary outcome of this meta-analysis was to assess
- 87 whether there was evidence for any structural changes in the hypothalamus in people with
- 88 AD or LBD using *in vivo* structural MRI. The secondary objective was to assess whether
- 89 there was an association between the structure of the hypothalamus and dementia
- 90 symptoms including changes to weight, sleep and endocrine function.
- 91

### 92 2.0 Methods

- 93 The protocol for the review was preregistered on PROSPERO
- 94 (https://www.crd.york.ac.uk/prospero/, registration number: CRD42024547743) and the
- 95 manuscript was produced using the PRISMA guidelines (Page et al., 2021).

### 96 <u>2.1 Search strategy</u>

- 97 We performed a systematic search of MEDLINE and EMBASE from inception to 15<sup>th</sup> May
- 98 2024 using the Ovid platform, to identify studies of people with AD or LBD which examined
- 99 the structure of the hypothalamus. The search string used was (hypothal\* AND (MRI or
- 100 magnetic resonance imaging) AND (Alzheimer\* OR DLB OR Lewy OR LBD OR Parkinson\*
- 101 disease dementia OR PDD)). Filters were used to limit the search to human studies in
- 102 English, using people aged 18 or over, published in "journal" or "report", and to remove
- 103 conference abstracts and duplicates.

## 104 <u>2.2 Eligibility criteria</u>

- 105 We only included studies using structural MRI imaging *in vivo* in humans, assessing the
- 106 volume of the hypothalamus, and excluded neuropathological studies and studies of
- 107 animals. Case studies and series, reviews, meta-analyses, conference abstracts and non-
- 108 peer reviewed material were also excluded.

## 109 <u>2.3 Data extraction and quality assessment</u>

- 110 Two authors (AASL and SNS) worked independently to screen the titles, abstracts and full-
- 111 texts to identify articles for inclusion using the online platform Rayyan (rayyan.ai). The
- reference lists of all included studies were reviewed to identify any further studies meeting
- the inclusion criteria. Any disagreements were resolved by discussion with a third reviewer
- 114 (BRU). The Newcastle-Ottawa scale for case-control studies was used to assess the quality
- and risk of bias of all included studies (Wells et al., 2021). This tool assesses non-
- 116 randomised studies using three domains (selection, comparability and exposure), to allow

117 studies to be stratified as being of "low" (8-9 points), "moderate" (6-7 points) or "high" (≤ 5 118 points) risk of bias. Data was extracted from the included studies using pre-defined tables. 119 For the meta-analysis, this included the mean hypothalamic volume, standard deviation and 120 sample size of the AD and control groups. For the narrative synthesis, this included any 121 qualitative evidence of group difference in hypothalamic volume (from whole brain voxel-122 based morphometry (VBM) studies), and associations between hypothalamic volume, weight 123 or appetite, sleep and endocrine function. Two studies met the inclusion criteria but did not 124 report sufficient quantitative data to be included in the meta-analysis. After contacting the 125 authors of both studies, one was able to provide the necessary additional data (Ofori et al., 126 2024), whereas the other study was included in the narrative synthesis but not the meta-127 analysis (Billot et al., 2020).

#### 128 <u>2.4 Statistical analysis</u>

129 A random-effects meta-analysis was conducted using the meta package in R studio (version 130 2021.09.0) to determine whether there was a difference in hypothalamic volume between 131 dementia and controls. The standardised mean difference (SMD, Cohen's d) between AD 132 and controls was calculated to homogenise the data, since studies reported volumetric 133 changes in the hypothalamus in different units (mm<sup>3</sup> or % of intracranial volume). Hedges' g 134 was then calculated and used as the effect size in the meta-analysis. This applies a small-135 sample correction factor to the Cohen's d, since the effect size can be overestimated in 136 studies with small sample sizes. A Hedges' g of 0.2 indicates a small effect, while 0.5 and 0.8 137 indicates a medium and large effect respectively. The percentage difference in volume for 138 each study was also calculated and averaged across the number of included studies since 139 this may be more easily interpretable. Heterogeneity (Tau<sup>2</sup>) was estimated using the 140 restricted maximum likelihood procedure, and Knapp-Hartung adjustment was applied to 141 control for the uncertainty of the between-study heterogeneity. The Q statistic was calculated 142 to assess whether the level of between-study heterogeneity was significant and the  $l^2$ 143 statistic was used to quantify this (25% = low, 50% = moderate, 75% = substantial) (Higgins and 144 Thompson, 2002). Publication bias was assessed by Egger's regression test, and by 145 inspection of the funnel plot. A narrative synthesis strategy was applied to assess whether 146 there was a relationship between structural changes and non-cognitive symptoms of 147 dementia.

148

## 149 <u>3.0 Results</u>

The article selection process is displayed in Figure 1. The search identified the titles andabstracts of 6542 articles which were screened to identify 63 articles for full-text review after

being marked for further consideration by at least one author. A list of the articles excluded

- 153 after full-text review is available in supplementary Table S1. Two articles were identified from
- 154 screening the reference lists of included studies and relevant review articles. This resulted in
- 155 the inclusion of 6 articles which provided quantitative measurements of hypothalamic volume
- 156 in AD that could be extracted for the meta-analysis (Grundman et al., 1996; Callen et al.,
- 157 2001; Loskutova et al., 2010; Ahmed et al., 2015; Chang et al., 2023; Ofori et al., 2024). A
- 158 further 6 studies reported qualitative changes in hypothalamic volume as part of whole brain
- 159 VBM, and/or associations between hypothalamic volume and clinical symptoms, and these
- 160 were included in the secondary narrative synthesis (Baron et al., 2001; Callen et al., 2004;
- 161 Whitwell et al., 2007; Hall et al., 2008; Kim et al., 2016; Billot et al., 2020). There was only
- 162 one study examining people with DLB using VBM, and no studies which included people
- 163 with PDD. The included studies had mostly (83%) a low, or moderate risk of bias, with only
- 164 two studies rated as high risk of bias. The extracted data is displayed in Table 1.
- 165 One study which initially appeared to meet the inclusion criteria, demonstrated that the
- 166 volume of the mamillary bodies, which is part of the posterior hypothalamus, was reduced in
- 167 people with AD compared to controls (Copenhaver et al., 2006). This was not included in the
- 168 data synthesis since it did not provide a volumetric measure for the full hypothalamus,
- although it is consistent with the findings of the included studies.
- 170 <u>3.1 Hypothalamic volume in AD and DLB versus controls</u>
- 171 The results of the random-effects meta-analysis is displayed in Figure 2, which includes data
- 172 from a total of 454 people with mild-moderate AD (MMSE range: 19.2-26.1) and 715 healthy
- 173 controls. The pooled standardised mean difference was -0.49 (t=-3.47, p=0.018, 95%CI: -
- 174 0.86 to -0.13), indicating that people with AD had a significantly smaller hypothalamus, a
- 175 difference which can be considered to be of a small-to-medium effect size. The between-
- 176 study heterogeneity variance was estimated at Tau<sup>2</sup> = 0.0665 (95%CI: 0.005-0.8090), I<sup>2</sup> =
- 177 67% (95%CI: 21.5%-86.1%) and Q = 15.16 (p<0.01). This indicates that there was
- 178 significant heterogeneity to a moderate degree. On average, the volume of the
- 179 hypothalamus was reduced by 10.1% (range: -29.4% to +0.73%) in people with AD
- 180 compared to controls. It is important to highlight that no study normalised their findings to the
- total grey matter volume, making it difficult to know whether the difference in hypothalamic
- volume is over and above the general grey matter atrophy which is seen in AD. The funnel
- 183 plot (Figure 3) was largely symmetrical and revealed no signs of publication bias. Egger's
- 184 regression test was not significant (intercept -2.16, p=0.23).
- Four studies used whole-brain VBM to provide a qualitative measure of differences in voxels
  between people with dementia and controls. Three of these reported grey matter loss in the

187 hypothalamus in people with AD (Baron et al., 2001; Whitwell et al., 2007; Hall et al., 2008), 188 while one did not report any differences (Kim et al., 2016). The only study using VBM in 189 people with DLB found grey matter loss in the hypothalamus in DLB compared to controls 190 (Whitwell et al., 2007). Billot et al. used an automatic segmentation pipeline and found 191 reduced volumes of all hypothalamic subunits in a large group of people with MCI and AD 192 compared to healthy controls, but did not provide sufficient volumetric data for inclusion in 193 the meta-analysis (Billot et al., 2020). The group differences were particularly pronounced in 194 the anterior-superior, anterior-inferior and the posterior hypothalamic subunits (Cohen's d =195 1.16, 0.99, 0.94 respectively), with a relative sparing of the inferior-tubular subunit (Cohen's 196 d = 0.34). Although, these studies are consistent with the results of the meta-analysis, there 197 may be other VBM studies comparing AD to healthy controls which did not specifically 198 mention the hypothalamus (due to a lack of an effect), and which were therefore not 199 captured by our search string.

## 200 <u>3.2 Hypothalamic volume in AD versus other neurodegenerative conditions</u>

- 201 There was no difference in hypothalamic volume in people with AD compared to DLB
- 202 (Whitwell et al., 2007), amyotrophic lateral sclerosis (ALS) (Chang et al., 2023), or
- 203 Parkinson's disease (Kim et al., 2016). One study found that people with behavioural variant
- frontotemporal dementia (bvFTD) had a significantly smaller hypothalamus compared to AD
- and controls (Ahmed et al., 2015). However, in this study the hypothalamic volume for the
- AD group were not different from the healthy controls, making the group differences difficult
- 207 to interpret.

#### 208 <u>3.3 Hypothalamus and weight</u>

- 209 There was no association between hypothalamic volume and body mass index (BMI)
- 210 (Grundman et al., 1996; Ahmed et al., 2015; Chang et al., 2023), or with eating habits as
- 211 measured by the Cambridge Behavioural Inventory (CBI) or the Appetite and Eating Habits
- 212 Questionnaire (APEHQ) (Ahmed et al., 2015). In all three studies the AD group had normal
- 213 or slightly raised BMI (mean: 23.8, 26.4, 26.6).

## 214 <u>3.4 Hypothalamus and sleep</u>

- 215 Higher score on the rapid eye movement (REM) sleep behaviour disorder screening
- 216 questionnaire, indicating symptoms of REM sleep behaviour disorder, was associated with
- 217 grey matter volume in the hypothalamus, although the association disappeared when
- 218 correcting for family-wise error (Kim et al., 2016).
- 219 <u>3.5 Hypothalamus and endocrine function</u>

220 Larger hypothalamic volume was associated with increased bone mineral density in AD 221 (r=0.34, p=0.007) (Loskutova et al., 2010). There was no significant association between 222 hypothalamic volume and plasma levels of appetite-regulating hormones, including leptin, 223 cholecystokinin, neuropeptide Y, agouti-related peptide, and peptide YY (Ahmed et al., 224 2015). Two studies reported that hypothalamic volume was smaller in men than women with 225 AD (Callen et al., 2004; Ofori et al., 2024), while one study with a high risk of bias found no 226 effect of sex (Chang et al., 2023). This effect was seen despite the males in the AD group 227 being at an earlier stage of illness than the females in one of the studies (Callen et al., 228 2004). Ofori et al. reported several associations between hypothalamic volume and plasma 229 levels of follicle stimulating hormone (FSH), luteinizing hormone (LH), progesterone and 230 testosterone, although these were not corrected for multiple comparisons (Ofori et al., 2024). 231 Increased volume of the inferior-tuberal subunit was weakly associated with levels of FSH 232 and LH in women with AD ( $R^2$ =0.11 (FSH), 0.12 (LH)), while no associations were found in 233 men with AD. In people with mild cognitive impairment (MCI), there were weak associations 234 between FSH, LH, progesterone, and testosterone and the volume of all hypothalamic 235 subunits apart from the anterior-inferior subunit ( $R^2$ =0.05-0.08). In healthy controls there 236 were associations between the inferior-tuberal subunit and progesterone ( $R^2$ =0.18 (men) 237 and  $R^2=0.38$  (women)), inferior-tuberal subunit and testosterone ( $R^2=0.20$  women only), 238 superior-tuberal subunit and testosterone (R<sup>2</sup>=0.20 men only), and posterior hypothalamus 239 and LH (R<sup>2</sup>=0.21 men and R<sup>2</sup>=0.21 women. This suggests that the association between 240 hypothalamic volume and plasma sex hormones weakens with worsened cognitive status.

241 In summary, multiple studies support that people with AD have a significantly lower

242 hypothalamic volume than controls. There has been one study in people with DLB with

similar findings. Furthermore, sex may influence hypothalamic volume loss, and decreased

244 hypothalamic volume may be associated with lower bone mineral density and plasma levels

of sex hormones although this needs further confirmation. No significant associations were

found with BMI or sleep.

247

## 248 4.0 Discussion

249 We found that people with AD have a smaller hypothalamus compared to healthy controls,

as measured by *in vivo* volumetric MRI imaging. Most of the studies investigated people with

251 mild-to-moderate AD, indicating that hypothalamic changes are present early in the clinical

252 course. A previous narrative review has described the role of the hypothalamus in AD,

although it only included evidence from 7 volumetric MRI studies (Ishii and Iadecola, 2015).

Here, we use both a meta-analytical and narrative approach to synthesise the evidence from

255 12 studies on the structure and function of the hypothalamus in AD and DLB, including 256 studies which uses recently developed automatic segmentation pipelines (Billot et al., 2020; 257 Chang et al., 2023; Ofori et al., 2024). The findings are consistent with neuropathological 258 studies which have found amyloid beta plaques and tau neurofibrillary tangles throughout 259 the hypothalamus in people with AD, associated with a reduced number of neurons and 260 morphological changes to organelles (Baloyannis et al., 2015; Braak and Braak, 1991; Lim 261 et al., 2014). Similarly, Lewy-body pathology has also been found in the hypothalamus of 262 people with PD, DLB and PDD (Benarroch et al., 2015; Braak et al., 2003; Kasanuki et al., 263 2014; Purba et al., 1994).

264 Our results are also consistent with studies using other MRI modalities, which have found 265 reduced glucose metabolism in the hypothalamus in people with MCI and AD using positron 266 emission tomography (Cross et al., 2013; Liguori et al., 2017; Nestor et al., 2003). One 267 study using single-photon emission computed tomography (SPECT) with the tracer <sup>123</sup>I-N- $\omega$ fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane (<sup>123</sup>I-FP-CIT) found that people 268 269 with DLB had lower serotonergic and/or dopaminergic binding in the hypothalamus 270 compared with healthy controls (Joling et al., 2019), although other SPECT studies in AD 271 have failed to demonstrate reduced perfusion in the hypothalamus (Callen et al., 2002, 2004; 272 Ismail et al., 2008; Lanctot et al., 2004, 2007). This discrepancy is likely a reflection of the 273 resolution of a SPECT scan being too low to detect any changes in a small structure such as 274 the hypothalamus without a specific tracer.

275 Studies in other neurodegenerative conditions using both manual and automatic

276 segmentation protocols have shown that the hypothalamus is smaller in all subtypes of FTD

277 (9-17% reduction) (Piguet et al., 2011; Ahmed et al., 2015; Bocchetta et al., 2015; Shapiro et

278 al., 2022; Tse et al., 2023), ALS (22% reduction) (Gorges et al., 2017; Liu et al., 2022; Tse et

al., 2023), in pre-symptomatic carriers of pathogenic FTD-ALS mutations (14% reduction)

280 (Gorges et al., 2017), and in spinocerebellar ataxia type 3 (3.40% reduction) (Guo et al.,

281 2022). A VBM study in people with Huntington's disease, suggested that hypothalamic

changes were present 9-15 years before the predicted time of clinical diagnosis (Soneson et

al., 2010), although another study using manual segmentation failed to find any cross-

sectional or longitudinal group differences (Gabery et al., 2015). Studies comparing different

types of dementia do not suggest that the magnitude of volume loss is significantly different

to that seen in AD and DLB. This suggests that the hypothalamus is vulnerable to

287 neurodegeneration secondary to a range of different pathologies. It is less well understood

whether the loss of volume in the hypothalamus contributes to the development of dementia,

symptomatology or whether this might be amenable to therapeutic intervention.

#### 290 <u>4.1 Hypothalamus and weight</u>

291 Physiologically, appetite is mediated by the hormones leptin and ghrelin, which is secreted 292 peripherally by adipose tissue and the stomach respectively (Coll et al., 2007). They have 293 opposing actions on the signalling between the arcuate and the paraventricular nuclei (PVN) 294 of the hypothalamus, to promote either satiety or increased appetite. Several studies have 295 assessed this pathway in people with bvFTD, which is commonly associated with binge-296 eating, a preference for sucrose and weight gain (Bang et al., 2015). People with bvFTD 297 overeat despite having a reduced plasma levels of ghrelin and raised leptin, indicating that 298 there is a central resistance to the effect of these hormones (Woolley et al., 2014). While 299 people with bvFTD had reduced volume of most hypothalamic subunits, there was a relative 300 sparing of the inferior-tubular subunit, which contains the arcuate nucleus (Shapiro et al., 301 2022; Tse et al., 2023). Furthermore, BMI and eating behaviour, as measured by CBI-R, is 302 negatively associated with the volume of the anterior-superior, anterior-inferior and posterior 303 subunits in bvFTD and ALS but not with the inferior-tubular subunit (Gorges et al., 2017; Liu 304 et al., 2022; Shapiro et al., 2022; Tse et al., 2023). These findings suggests that the 305 dysregulated appetite in bvFTD is not due to changes in the signalling to the arcuate nucleus 306 but may instead be due to changes in higher order nuclei, such as the PVN, or in other areas 307 of the brain. Interestingly, the inferior-tubular subunit was relatively preserved in AD on MRI 308 imaging (Billot et al., 2020), while neuropathological studies have found that in this nucleus 309 is either unaffected by pathology (Purba et al., 1994; Saper and German, 1987), or only 310 affected by pathology in men (Schultz et al., 1996, 1999). This suggests that the arcuate 311 nucleus may be more resistant to neurodegeneration than other hypothalamic nuclei. Weight 312 loss is common in both AD and LBD, and this is associated with an increased rate of 313 mortality and emergency hospitalisation (Soysal et al., 2021). Although there was no 314 association between appetite or BMI and hypothalamic volume in AD (Grundman et al., 315 1996; Ahmed et al., 2015; Chang et al., 2023), this may be due to the normal or slightly 316 raised BMI of people with AD in these studies. Longitudinal studies are needed to assess 317 whether weight loss is related to hypothalamic volume in AD or DLB, and whether the 318 subunit-specific associations are similar to those observed in bvFTD.

#### 319 <u>4.2 Hypothalamus and sleep</u>

320 Sleep disturbance is very common in people living with dementia, with an estimated

- 321 prevalence of 24% in Alzheimer's disease and 49% in Lewy body dementia (Koren et al.,
- 322 2023). This is a significant issue both for people with dementia and their caregivers where
- 323 sleep disturbance is associated with carer stress and need for institutional care. Although the
- 324 underlying causes are likely to be multifactorial, it is possible that it involves

325 neurodegeneration of the hypothalamus, since this structure is essential for the regulation of 326 sleep and wakefulness. Wakefulness is promoted by the histaminergic tuberomammillary 327 nucleus (TMN) in the posterior hypothalamus, while sleep is promoted by the GABA and 328 galanin producing neurons of the ventrolateral preoptic nucleus (VLPO) in the anterior 329 hypothalamus (Saper et al., 2005). The lateral hypothalamus modifies this system through 330 orexin, which promotes wakefulness, and melanin-concentrating hormone, which promotes 331 sleep. The 24-hour circadian rhythm is maintained by the suprachiasmatic nucleus (SCN) in 332 the anterior-inferior hypothalamus, which influences the VLPO and lateral hypothalamus via 333 its connections to the dorsomedial nucleus. Disruptions to this complex system can cause 334 sleep-disorders, such in the case of narcolepsy which is characterized by a selective loss of 335 orexin-producing neurons (Saper et al., 2005). Neuropathological studies have shown that 336 people with DLB and AD had fewer neurons in the VLPO, SCN and TMN compared to 337 controls, with associations between the number of neurons and sleep fragmentation, 338 circadian rhythm and core body temperature (Harper et al., 2008; Fronczek et al., 2012; 339 Shan et al., 2012; Kasanuki et al., 2014; Lim et al., 2014). 340 In contrast, in vivo studies have found that people with MCI and AD have increased levels of 341 CSF orexin compared with controls, with an association between orexin levels and disrupted 342 sleep metrics (Liguori et al., 2014, 2016, 2017; Gabelle et al., 2017). In DLB and PDD, 343 studies have failed to demonstrate any alterations in CSF orexin or any relationship between

orexin and changes in sleep (Yasui et al., 2006; Compta et al., 2009). Furthermore,

345 treatment with suvorexant, a dual orexin receptor antagonist, have received Food and Drug

346 Administration (FDA) approval for the treatment of insomnia in Alzheimer's disease after it

347 was shown to increased total sleep time and reduce waking after sleep onset compared to

348 placebo (Herring et al., 2020). Suvorexant also acutely reduce the concentration of CSF

- amyloid beta and ptau181/tau181 ratio in healthy volunteers (Lucey et al., 2023), and a
- 350 longitudinal trial in people at risk of AD is ongoing
- 351 (https://clinicaltrials.gov/study/NCT04629547). Only two small MRI studies have examined
- 352 association between hypothalamus and sleep in AD, finding a significant association
- 353 between reduced hypothalamic glucose uptake and increased sleep disturbances (Liguori et
- al., 2017), and a trend towards higher REM sleep behaviour disorder score and grey matter
- signal on VBM (Kim et al., 2016). Further studies will need to clarify how a reduction in
- 356 hypothalamic volume relates to an increase in CSF orexin in AD.
- 357 <u>4.3 Hypothalamus and endocrine function</u>

358 In addition to maintaining weight, appetite and sleep, the hypothalamus is an important

359 regulator of several endocrine glands. The HPA axis starts with secretion of corticotrophin-

360 releasing hormone (CRH) from the PVN, which in turn stimulates secretion of 361 adrenocorticotropic hormone (ACTH) from the pituitary gland (Ahmad et al., 2019). This 362 stimulates the secretion of glucocorticoids, such as cortisol, from the adrenal glands which 363 acts through a negative feedback loop on the hypothalamus and pituitary gland to limit its 364 own secretion. People with MCI and AD have higher levels of cortisol in plasma and CSF 365 (Csernansky et al., 2006; Popp et al., 2015), an abnormal dexamethasone suppression test 366 (O'Brien et al., 1996; Elgh et al., 2006), and increased CRH production in the PVN compared 367 to healthy controls (Raadsheer et al., 1995). Furthermore, these abnormalities were 368 associated with higher cerebral amyloid burden (Toledo et al., 2012), increased hippocampal 369 atrophy (O'Brien et al., 1996; Elgh et al., 2006; Huang et al., 2009), and more rapid decline 370 on cognitive tests (Huang et al., 2009; Popp et al., 2015), indicating that dysfunction of the 371 HPA axis may contribute to the progression of the disease.

372 Similarly, the HPG axis consists of gonadotrophin-releasing hormone (GnRH) which is 373 secreted in a pulsatile manner from the arcuate nucleus of the hypothalamus to stimulate the 374 secretion of follicle-stimulating hormone (FSH) and luteinising hormone (LH) from the 375 anterior pituitary gland (Desai et al., 2021). FSH and LH in turn stimulate the release of sex 376 hormones (testosterone, oestrogens and progesterone) from the gonads which acts through 377 a negative feedback loop on the hypothalamus and pituitary to regulate the HPG axis. The 378 decline in plasma levels of neuroprotective sex hormones after menopause, may explain 379 why AD is more prevalent in women than men (Livingston et al., 2024). However, a meta-380 analysis of randomised clinical trials found that hormone replacement therapy with oestrogen 381 and progesterone after menopause was associated with an increased risk of dementia, 382 although the timing of initiation, type of formulation and duration of treatment may modify this 383 risk (Zhou et al., 2021). It is also possible that an increase in GnRH, FSH and LH which also 384 occurs because of menopause may contribute to the increased risk of AD in women. 385 Increased levels of FSH and LH, were associated with higher amyloid load, reduced grey 386 matter volume and hippocampal loss independent of age and menopause status (Nerattini et 387 al., 2023).

388 A similar pattern is seen in men with AD, who have lower levels of testosterone and higher 389 levels of FSH and LH compared to controls (Bowen et al., 2000; Butchart et al., 2013). One 390 ecological study suggests that men who have had treatment with an GnRH agonists for 391 prostate cancer, had a lower risk of developing AD compared to people who underwent other 392 procedures (Smith et al., 2018). GnRH agonists work by continuously stimulating the GnRH 393 receptor in the pituitary which initially causes a spike in FSH. LH and testosterone 394 production, followed by downregulation of GnRH receptors in the pituitary gland (Desai et al., 395 2021). The result is a reduction of FSH, LH and testosterone. The only study using

396 hypothalamic segmentation to investigate the HPG axis in AD, found that the volume of the 397 inferior tubular subunit, which contains the arcuate nucleus, was associated with plasma 398 levels of FSH and LH in women, but not men, with AD (Ofori et al., 2024). Furthermore, in 399 healthy controls and people with MCI, there was a more widespread associations between 400 hypothalamic volume and plasma levels of FSH, LH, progesterone and testosterone. The 401 hypothalamus is one of the most highly sexually dimorphic areas of the brain, with healthy 402 men having a larger hypothalamus than women (Goldstein et al., 2001). Conversely, two 403 studies in the current review found that men with AD have a smaller hypothalamus than 404 women (Callen et al., 2004; Ofori et al., 2024), a finding which is consistent with the 405 neuropathological studies of the arcuate nucleus which is almost exclusively affected by AD 406 pathology in men but not women (Schultz et al., 1996, 1999). Overall, these studies provide 407 further indication that hypothalamic pathology may be relevant to explain the sex

408 discrepancy seen in AD.

409 Hypothalamic pathology in AD may also have an impact on other hormones which are 410 secreted by the hypothalamus, including growth-hormone releasing hormone (GHRH) and 411 thyrotropin releasing hormone (TRH). In people with MCI, treatment with GHRH analogues 412 improves executive function and levels of insulin-like-growth factor 1 (Baker et al., 2012), 413 and lower plasma levels of this hormone are associated with an increased risk of developing 414 AD (Westwood et al., 2014). Furthermore, a meta-analysis found that a both an increased 415 levels of thyroid stimulating hormone (TSH) (indicating primary hypothyroidism) and reduced 416 TSH levels (indicating primary hyperthyroidism) were associated with an increase in risk of 417 developing dementia (Tang et al., 2021). Overall, people with established AD have lower 418 triiodothyronine (T3), but no difference in TSH or thyroxine (T4) compared to controls 419 (Dolatshahi et al., 2023), while a central pattern of hypothyroidism (reduced TRH, TSH, T3 420 and T4) may be seen in people with advanced AD (Chen et al., 2013; Yong-Hong et al., 421 2013).

422 The new automatic segmentation pipelines will be useful for future studies to determine 423 whether the abnormalities seen in the HPA, HPG, the hypothalamic-pituitary-thyroid and the 424 hypothalamic-pituitary-somatotropic (growth hormone) axes in people with AD are related to 425 hypothalamic pathology. This may have important implications for new treatment targets and 426 to understand the increased prevalence of osteoporosis in people with AD (Xie et al., 2023). 427 On study has found that bone mineral density was associated with hypothalamic volume in 428 AD, but not in healthy controls (Loskutova et al., 2010). Many of the hormones under 429 hypothalamic control influence bone homeostasis, as seen by the prevalence of 430 osteoporosis in people with early menopause, and in conditions such as

431 hyperprolactinaemia, hyperthyroidism and hypocortisolaemia (Niwczyk et al., 2023). In

432 addition to the hormonal route, neuronal signalling from the hypothalamic nuclei also act

directly on osteoblasts through their innervation by the sympathetic nervous system

434 (Niwczyk et al., 2023). Understanding the causes of osteoporosis in AD is important due to

the significantly higher risk of bone fractures, which in turn is associated with a significant

436 morbidity and mortality.

#### 437 <u>4.4 Limitations</u>

438 Most of the studies included in this review were small case-control studies, introducing 439 possible bias, and limiting the generalisability of the conclusions to the general population of 440 people with AD. The meta-analysis had significant between-study heterogeneity, which is 441 likely a reflection of the variation in the study population size, MRI acquisition protocol and 442 analysis protocol. The inclusion of people with different stages of AD may also have 443 contributed to the heterogeneity, although the range of cognitive scores (MMSE range: 19.2-444 26.1) suggests that most people had mild-to-moderate dementia. Despite the heterogeneity 445 in study design, only two studies (Ahmed et al., 2015; Kim et al., 2016) did not find a 446 significant difference in hypothalamic volume, while no study reported a larger hypothalamus 447 in AD. While there was no suggestion of publication bias, the small number of included 448 studies which could be included in the meta-analysis may have made the funnel plot difficult 449 to interpret. Finally, due to the absence of longitudinal studies, or studies using AD 450 biomarkers, it is not possible to make any firm conclusions about the cause of a smaller 451 hypothalamus, or the changes in volume across the AD disease process.

452

## 453 **5.0 Conclusion**

454 In this meta-analysis, we found evidence that the hypothalamus is smaller in people with AD 455 (-10.1%) compared to healthy controls, as shown by *in vivo* MRI structural imagining. One 456 study also found qualitative evidence that the hypothalamus is reduced in DLB, but further 457 studies are required to confirm this finding. Hypothalamic volume is also smaller in other 458 neurodegenerative conditions, in particular FTD and ALS, suggesting that the hypothalamus 459 may be vulnerable to neurodegeneration in the context of many different pathological 460 processes. Hypothalamic volume loss may be greater in men than women, and the arcuate 461 nuclei may be affected less than others. Finally, a smaller hypothalamus may be associated 462 with plasma levels of sex hormones and reduced bone mineral density in AD, indicating that 463 hypothalamic involvement may have specific functional consequences. Further studies will 464 need to assess how hypothalamic pathology evolves during the disease process in AD and 465 LBD and its impact on weight, sleep, endocrine function and clinically meaningful 466 symptomatology.

## 467

# 468 6.0 Funding sources

- 469 This research did not receive any specific grant from funding agencies in the public,
- 470 commercial, or not-for-profit sectors.

471

# 472 7.0 Declaration of interest

- 473 AASL's post is funded by a grant from Altos labs and is a member of the National Institute for
- 474 Health and Care Research (NIHR) Dementia Portfolio Development Group. This research
- 475 was supported by the NIHR Cambridge Biomedical Research Centre (NIHR203312) and the
- 476 Cambridge Centre for Parkinson's Plus Disorders. The views expressed are those of the
- 477 authors and not necessarily those of the NIHR or the Department of Health and Social Care.
- 478 Data from this project will also be included as part of a PhD thesis by AASL. BRU is the R&D
- director at his trust, CRN lead for dementia for the East of England and national CRN lead
- 480 for stratified medicine in dementia. He is the vice-chair of the faculty of old age psychiatry in
- 481 the Royal College of Psychiatry. His post is part funded by a generous donation from
- 482 Gnodde Goldman Sachs gives. He has served in a paid role on an advisory boards for Lilly
- 483 and TauRx.
- 484

# 485 8.0 Data availability

486 Data is available from the corresponding author upon reasonable request.

487

## 488 9.0 References

489	Ahmad, M.H., Fatima, M., Mondal, A.C., 2019. Role of hypothalamic-pituitary-adrenal axis,
490	hypothalamic-pituitary-gonadal axis and insulin signaling in the pathophysiology of
491	Alzheimer's disease. Neuropsychobiology. 77, 197–205. https://doi.org/10.1159/000495521
492	
493	Ahmed, R., Latheef, S., Bartley, L., Irish, M., Halliday, G., Kiernan, M., Hodges, J., Piguet,
494	O., 2015. Eating behavior in frontotemporal dementia: peripheral hormones vs hypothalamic
495 496	pathology. Neurology. 85, 1310-1317. https://doi.org/10.1212/WNL.000000000002018
497	Baker, L.D., Barsness, S.M., Borson, S., Merriam, G.R., Friedman, S.D., Craft, S., Vitiello,
498	M.V., 2012. Effects of growth hormone–releasing hormone on cognitive function in adults
499	with mild cognitive impairment and healthy older adults. Arch. Neurol. 69, 1420–1429.
500	https://doi.org/10.1001/archneurol.2012.1970
501	
502	Baloyannis, S.J., Mavroudis, I., Mitilineos, D., Baloyannis, I.S., Costa, V.G., 2015. The
503	hypothalamus in Alzheimer's disease: a golgi and electron microscope study. Am. J.
504	Alzheimers. Dis. Other. Demen. 30, 478–487. https://doi.org/10.1177/1533317514556876
505	
506	Bang, J., Spina, S., Miller, B.L., 2015. Frontotemporal dementia. Lancet. 386, 1672–1682.
507	https://doi.org/10.1016/S0140-6736(15)00461-4
508	
509	Baron, J.C., Chételat, G., Desgranges, B., Perchey, G., Landeau, B., de la Sayette, V.,
510	Eustache, F., 2001. In vivo mapping of gray matter loss with voxel-based morphometry in
511	mild Alzheimer's disease. Neuroimage. 14, 298–309.
512	https://doi.org/10.1006/nimg.2001.0848
513	
514	Benarroch, E.E., Schmeichel, A.M., Parisi, J.E., Low, P.A., 2015. Histaminergic
515	tuberomammillary neuron loss in multiple system atrophy and dementia with Lewy bodies.
516	Mov. Disord. 30, 1133–1139. https://doi.org/10.1002/mds.26287
517	
518	Billot, B., Bocchetta, M., Todd, E., Dalca, A.V., Rohrer, J.D., Iglesias, J.E., 2020. Automated
519	segmentation of the hypothalamus and associated subunits in brain MRI. Neuroimage. 223,
520	117287. https://doi.org/10.1016/j.neuroimage.2020.117287
521	
522	Bocchetta, M., Gordon, E., Manning, E., Barnes, J., Cash, D.M., Espak, M., Thomas, D.L.,
523	Modat, M., Rossor, M.N., Warren, J.D., Ourselin, S., Frisoni, G.B., Rohrer, J.D., 2015.

524	Detailed volumetric analysis of the hypothalamus in behavioral variant frontotemporal
525	dementia. J. Neurol. 262, 2635–2642. https://doi.org/10.1007/s00415-015-7885-2
526	
527	Bowen, R.L., Isley, J.P., Atkinson, R.L., 2000. An association of elevated serum gonadotropin
528	concentrations and Alzheimer disease? J. Neuroendocrinol. 12, 351–354.
529	https://doi.org/10.1046/j.1365-2826.2000.00461.x
530	
531	Braak, H., Braak, E., 1991. Neuropathological stageing of Alzheimer-related changes. Acta.
532	Neuropathol. 82, 239–259. https://doi.org/10.1007/BF00308809
533	
534	Braak, H., Del Tredici, K., Rüb, U., de Vos, R.A.I., Jansen Steur, E.N.H., Braak, E., 2003.
535	Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging. 24,
536	197–211. https://doi.org/10.1016/s0197-4580(02)00065-9
537	
538	Butchart, J., Birch, B., Bassily, R., Wolfe, L., Holmes, C., 2013. Male sex hormones and
539	systemic inflammation in Alzheimer disease. Alzheimer. Dis. Assoc. Disord. 27, 153–156.
540	https://doi.org/10.1097/WAD.0b013e318258cd63
541	
542	Callen, D., Black, S., Caldwell, C., 2002. Limbic system perfusion in Alzheimer's disease
543	measured by MRI-coregistered HMPAO SPET. Eur. J. Nucl. Med. Mol. Imaging. 29, 899-906.
544	https://doi.org/10.1007/s00259-002-0816-3
545	
546	Callen, D., Black, S., Caldwell, C., Grady, C., 2004. The influence of sex on limbic volume
547	and perfusion in AD. Neurobiol. Aging. 25, 761-770.
548	https://doi.org/10.1016/j.neurobiolaging.2003.08.011
549	
550	Orling D. Directo O. Ora E. Orling II. O. Oralei, J. 2024. Devendular biogrammers MDI
	Callen, D., Black, S., Gao, F., Caldwell, C., Szalai, J., 2001. Beyond the hippocampus: MRI
551	volumetry confirms widespread limbic atrophy in AD. Neurology. 57, 1669-1674.
551 552	
	volumetry confirms widespread limbic atrophy in AD. Neurology. 57, 1669-1674.
552	volumetry confirms widespread limbic atrophy in AD. Neurology. 57, 1669-1674.
552 553	volumetry confirms widespread limbic atrophy in AD. Neurology. 57, 1669-1674. https://doi.org/10.1212/wnl.57.9.1669
552 553 554	volumetry confirms widespread limbic atrophy in AD. Neurology. 57, 1669-1674. https://doi.org/10.1212/wnl.57.9.1669 Chang, J., Shaw, T.B., Holdom, C.J., McCombe, P.A., Henderson, R.D., Fripp, J., Barth, M.,
552 553 554 555	volumetry confirms widespread limbic atrophy in AD. Neurology. 57, 1669-1674. https://doi.org/10.1212/wnl.57.9.1669 Chang, J., Shaw, T.B., Holdom, C.J., McCombe, P.A., Henderson, R.D., Fripp, J., Barth, M., Guo, C.C., Ngo, S.T., Steyn, F.J., Alzheimer's Disease Neuroimaging Initiative, 2023. Lower
552 553 554 555 556	volumetry confirms widespread limbic atrophy in AD. Neurology. 57, 1669-1674. https://doi.org/10.1212/wnl.57.9.1669 Chang, J., Shaw, T.B., Holdom, C.J., McCombe, P.A., Henderson, R.D., Fripp, J., Barth, M., Guo, C.C., Ngo, S.T., Steyn, F.J., Alzheimer's Disease Neuroimaging Initiative, 2023. Lower hypothalamic volume with lower body mass index is associated with shorter survival in

- 560 Chang, J., Steyn, F., Ngo, S., Henderson, R., Guo, C., Bollmann, S., Fripp, J., Barth, M.,
- 561 Shaw, T., 2022. Open-source hypothalamic-forniX (OSHy-X) atlases and segmentation tool
- 562 for 3T and 7T. Journal of Open Source Software. 7, 4368.
- 563 https://doi.org/10.21105/joss.04368
- 564
- 565 Chen, J.-M., Huang, C.-Q., Ai, M., Kuang, L., 2013. Circadian rhythm of TSH levels in
- subjects with Alzheimer's disease (AD). Aging. Clin. Exp. Res. 25, 153–157.
- 567 https://doi.org/10.1007/s40520-013-0025-x
- 568
- 569 Coll, A.P., Farooqi, I.S., O'Rahilly, S., 2007. The hormonal control of food intake. Cell. 129,
- 570 251–262. https://doi.org/10.1016/j.cell.2007.04.001
- 571
- 572 Compta, Y., Santamaria, J., Ratti, L., Tolosa, E., Iranzo, A., Muñoz, E., Valldeoriola, F.,
- 573 Casamitjana, R., Ríos, J., Marti, M.J., 2009. Cerebrospinal hypocretin, daytime sleepiness
- and sleep architecture in Parkinson's disease dementia. Brain. 132, 3308–3317.
- 575 https://doi.org/10.1093/brain/awp263
- 576
- 577 Copenhaver, B.R., Rabin, L.A., Saykin, A.J., Roth, R.M., Wishart, H.A., Flashman, L.A.,
- 578 Santulli, R.B., McHugh, T.L., Mamourian, A.C., 2006. The fornix and mammillary bodies in
- 579 older adults with Alzheimer's disease, mild cognitive impairment, and cognitive complaints: a
- volumetric MRI study. Psychiatry. Res. 147, 93–103.
- 581 https://doi.org/10.1016/j.pscychresns.2006.01.015
- 582
- Cross, D.J., Anzai, Y., Petrie, E.C., Martin, N., Richards, T.L., Maravilla, K.R., Peskind, E.R.,
  Minoshima, S., 2013. Loss of olfactory tract integrity affects cortical metabolism in the brain
  and olfactory regions in aging and mild cognitive impairment. J. Nucl. Med. 54, 1278–1284.
  https://doi.org/10.2967/jnumed.112.116558
- 587
- 588 Csernansky, J.G., Dong, H., Fagan, A.M., Wang, L., Xiong, C., Holtzman, D.M., Morris, J.C.,
- 589 2006. Plasma cortisol and progression of dementia in subjects with Alzheimer-type
- dementia. Am. J. Psychiatry. 163, 2164–2169. https://doi.org/10.1176/ajp.2006.163.12.2164
  591
- 592 Desai, K., McManus, J.M., Sharifi, N., 2021. Hormonal therapy for prostate cancer. Endocr.
- 593 Rev. 42, 354–373. https://doi.org/10.1210/endrev/bnab002
- 594
- 595 Dolatshahi, M., Salehipour, A., Saghazadeh, A., Sanjeari Moghaddam, H., Aghamollaii, V.,
- 596 Fotouhi, A., Tafakhori, A., 2023. Thyroid hormone levels in Alzheimer disease: a systematic

- review and meta-analysis. Endocrine. 79, 252–272. https://doi.org/10.1007/s12020-02203190-w
- 599
- Elgh, E., Lindqvist Astot, A., Fagerlund, M., Eriksson, S., Olsson, T., Näsman, B., 2006.
- 601 Cognitive dysfunction, hippocampal atrophy and glucocorticoid feedback in Alzheimer's
- 602 disease. Biol. Psychiatry. 59, 155–161. https://doi.org/10.1016/j.biopsych.2005.06.017 603
- Fronczek, R., van Geest, S., Frölich, M., Overeem, S., Roelandse, F.W.C., Lammers, G.J.,
- 605 Swaab, D.F., 2012. Hypocretin (orexin) loss in Alzheimer's disease. Neurobiol. Aging. 33,
- 606 1642–1650. https://doi.org/10.1016/j.neurobiolaging.2011.03.014
- 607
- Gabelle, A., Jaussent, I., Hirtz, C., Vialaret, J., Navucet, S., Grasselli, C., Robert, P.,
- Lehmann, S., Dauvilliers, Y., 2017. Cerebrospinal fluid levels of orexin-A and histamine, and
- 610 sleep profile within the Alzheimer process. Neurobiol. Aging. 53, 59–66.
- 611 https://doi.org/10.1016/j.neurobiolaging.2017.01.011
- 612
- Gabery, S., Georgiou-Karistianis, N., Lundh, S.H., Cheong, R.Y., Churchyard, A., Chua, P.,
- 614 Stout, J.C., Egan, G.F., Kirik, D., Petersén, Å., 2015. Volumetric analysis of the
- 615 hypothalamus in Huntington disease using 3T MRI: the IMAGE-HD study. PLoS One. 10,
- 616 e0117593. https://doi.org/10.1371/journal.pone.0117593
- 617
- 618 Goldstein, J.M., Seidman, L.J., Horton, N.J., Makris, N., Kennedy, D.N., Caviness, V.S.,
- 619 Faraone, S.V., Tsuang, M.T., 2001. Normal sexual dimorphism of the adult human brain
- 620 assessed by in vivo magnetic resonance imaging. Cereb. Cortex. 11, 490–497.
- 621 https://doi.org/10.1093/cercor/11.6.490
- 622
- 623 Goodman, R.A., Lochner, K.A., Thambisetty, M., Wingo, T.S., Posner, S.F., Ling, S.M., 2017.
- 624 Prevalence of dementia subtypes in United States Medicare fee-for-service beneficiaries,
- 625 2011–2013. Alzheimers Dement. 13, 28–37. https://doi.org/10.1016/j.jalz.2016.04.002
- 626
- 627 Gorges, M., Vercruysse, P., Müller, H.-P., Huppertz, H.-J., Rosenbohm, A., Nagel, G., Weydt,
- 628 P., Petersén, Å., Ludolph, A.C., Kassubek, J., Dupuis, L., 2017. Hypothalamic atrophy is
- 629 related to body mass index and age at onset in amyotrophic lateral sclerosis. J. Neurol.
- 630 Neurosurg. Psychiatry. 88, 1033–1041. https://doi.org/10.1136/jnnp-2017-315795
- 631

632 Grundman, M., Corey-Bloom, J., Jernigan, T., Archibald, S., Thal, L., 1996. Low body weight

- 633 in Alzheimer's disease is associated with mesial temporal cortex atrophy. Neurology. 46,
- 634 1585-1591. https://doi.org/10.1212/wnl.46.6.1585
- 635
- Guo, J., Jiang, Z., Biswal, B.B., Zhou, B., Xie, D., Gao, Q., Sheng, W., Chen, Hui, Zhang, Y.,
- 637 Fan, Y., Wang, J., Liu, C., Chen, H., 2022. Hypothalamic atrophy, expanded CAG repeat,
- and low body mass index in spinocerebellar ataxia type 3. Mov. Disord. 37, 1541–1546.
- 639 https://doi.org/10.1002/mds.29029
- 640
- Hall, A.M., Moore, R.Y., Lopez, O.L., Kuller, L., Becker, J.T., 2008. Basal forebrain atrophy is
- a presymptomatic marker for Alzheimer's disease. Alzheimers. Dement. 4, 271–279.
- 643 https://doi.org/10.1016/j.jalz.2008.04.005
- 644
- Harper, D.G., Stopa, E.G., Kuo-Leblanc, V., McKee, A.C., Asayama, K., Volicer, L., Kowall,
- N., Satlin, A., 2008. Dorsomedial SCN neuronal subpopulations subserve different functions
- 647 in human dementia. Brain. 131, 1609–1617. https://doi.org/10.1093/brain/awn049
- 648
- 649 Herring, W.J., Ceesay, P., Snyder, E., Bliwise, D., Budd, K., Hutzelmann, J., Stevens, J.,
- Lines, C., Michelson, D., 2020. Polysomnographic assessment of suvorexant in patients with
- 651 probable Alzheimer's disease dementia and insomnia: a randomized trial. Alzheimers.
- 652 Dement. 16, 541–551. https://doi.org/10.1002/alz.12035
- 653
- Higgins, J.P.T., Thompson, S.G., 2002. Quantifying heterogeneity in a meta-analysis. Stat.
- 655 Med. 21, 1539–1558. https://doi.org/10.1002/sim.1186
- 656
- 657 Huang, C.-W., Lui, C.-C., Chang, W.-N., Lu, C.-H., Wang, Y.-L., Chang, C.-C., 2009.
- 658 Elevated basal cortisol level predicts lower hippocampal volume and cognitive decline in
- Alzheimer's disease. J. Clin. Neurosci. 16, 1283–1286.
- 660 https://doi.org/10.1016/j.jocn.2008.12.026
- 661
- 662 Ishii, M., Iadecola, C., 2015. Metabolic and non-cognitive manifestations of Alzheimer's
- disease: the hypothalamus as both culprit and target of pathology. Cell. Metab. 22, 761–776.
- 664 https://doi.org/10.1016/j.cmet.2015.08.016
- 665
- 666 Ismail, Z., Herrmann, N., Rothenburg, L., Cotter, A., Leibovitch, F., Rafi-Tari, S., Black, S.,
- 667 Lanctot, K., 2008. A functional neuroimaging study of appetite loss in Alzheimer's disease. J.
- 668 Neurol. Sci. 271, 97-103. https://doi.org/10.1016/j.jns.2008.03.023

669	
670	Joling, M., Vriend, C., Raijmakers, P.G.H.M., van der Zande, J.J., Lemstra, A.W., Berendse,
671	H.W., Booij, J., van den Heuvel, O.A., 2019. Striatal DAT and extrastriatal SERT binding in
672	early-stage Parkinson's disease and dementia with Lewy bodies, compared with healthy
673	controls: an 123I-FP-CIT SPECT study. Neuroimage. Clin. 22, 101755.
674	https://doi.org/10.1016/j.nicl.2019.101755
675	
676	Kasanuki, K., Iseki, E., Kondo, D., Fujishiro, H., Minegishi, M., Sato, K., Katsuse, O., Hino,
677	H., Kosaka, K., Arai, H., 2014. Neuropathological investigation of hypocretin expression in
678	brains of dementia with Lewy bodies. Neurosci. Lett. 569, 68–73.
679	https://doi.org/10.1016/j.neulet.2014.03.020
680	
681	Kim, HJ., Im, H., Kim, J., Han, JY., De Leon, M., Deshpande, A., Moon, WJ., 2016. Brain
682	atrophy of secondary REM-sleep behavior disorder in neurodegenerative disease. J.
683	Alzheimers. Dis. 52, 1101-1109. https://doi.org/10.3233/JAD-151197
684	
685	Koren, T., Fisher, E., Webster, L., Livingston, G., Rapaport, P., 2023. Prevalence of sleep
686	disturbances in people with dementia living in the community: a systematic review and meta-
687	analysis. Ageing. Res. Rev. 83, 101782. https://doi.org/10.1016/j.arr.2022.101782
688	
689	Lanctot, K., Herrmann, N., Nadkarni, N., Leibovitch, F., Caldwell, C., Black, S., 2004. Medial
690	Temporal Hypoperfusion and Aggression in Alzheimer Disease. Arch. Neurol. 61, 1731-1737.
691	https://doi.org/10.1001/archneur.61.11.1731
692	
693	Lanctot, K., Moosa, S., Herrmann, N., Leibovitch, F., Rothenburg, L., Cotter, A., Black, S.,
694	2007. A SPECT study of apathy in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 24,
695	65-72. https://doi.org/10.1159/000103633
696	
697	Liguori, C., Chiaravalloti, A., Nuccetelli, M., Izzi, F., Sancesario, G., Cimini, A., Bernardini, S.,
698	Schillaci, O., Mercuri, N., Fabio, P., 2017. Hypothalamic dysfunction is related to sleep
699	impairment and CSF biomarkers in Alzheimer's disease. J. Neurol. 264, 2215-2223.
700	https://doi.org/10.1007/s00415-017-8613-x
701	
702	Liguori, C., Nuccetelli, M., Izzi, F., Sancesario, G., Romigi, A., Martorana, A., Amoroso, C.,
703	Bernardini, S., Marciani, M.G., Mercuri, N.B., Placidi, F., 2016. Rapid eye movement sleep
704	disruption and sleep fragmentation are associated with increased orexin-A cerebrospinal-

fluid levels in mild cognitive impairment due to Alzheimer's disease. Neurobiol. Aging. 40,

706 120–126. https://doi.org/10.1016/j.neurobiolaging.2016.01.007

707

Liguori, C., Romigi, A., Nuccetelli, M., Zannino, S., Sancesario, G., Martorana, A., Albanese,

- M., Mercuri, N.B., Izzi, F., Bernardini, S., Nitti, A., Sancesario, G.M., Sica, F., Marciani, M.G.,
- 710 Placidi, F., 2014. Orexinergic system dysregulation, sleep impairment, and cognitive decline
- in Alzheimer disease. JAMA. Neurol. 71, 1498–1505.
- 712 https://doi.org/10.1001/jamaneurol.2014.2510
- 713
- Lim, A.S.P., Ellison, B.A., Wang, J.L., Yu, L., Schneider, J.A., Buchman, A.S., Bennett, D.A.,
- 715 Saper, C.B., 2014. Sleep is related to neuron numbers in the ventrolateral

716 preoptic/intermediate nucleus in older adults with and without Alzheimer's disease. Brain.

717 137, 2847–2861. https://doi.org/10.1093/brain/awu222

718

Liu, S., Ren, Q., Gong, G., Sun, Y., Zhao, B., Ma, X., Zhang, N., Zhong, S., Lin, Y., Wang,

- 720 W., Zheng, R., Yu, X., Yun, Y., Zhang, D., Shao, K., Lin, P., Yuan, Y., Dai, T., Zhang, Y., Li, L.,
- Li, W., Zhao, Y., Shan, P., Meng, X., Yan, C., 2022. Hypothalamic subregion abnormalities

are related to body mass index in patients with sporadic amyotrophic lateral sclerosis. J.

723 Neurol. 269, 2980–2988. https://doi.org/10.1007/s00415-021-10900-3

- 724
- Livingston, G., Huntley, J., Liu, K.Y., Costafreda, S.G., Selbæk, G., Alladi, S., Ames, D.,
- 726 Banerjee, S., Burns, A., Brayne, C., Fox, N.C., Ferri, C.P., Gitlin, L.N., Howard, R., Kales,
- H.C., Kivimäki, M., Larson, E.B., Nakasujja, N., Rockwood, K., Samus, Q., Shirai, K., Singh-
- Manoux, A., Schneider, L.S., Walsh, S., Yao, Y., Sommerlad, A., Mukadam, N., 2024.
- 729 Dementia prevention, intervention, and care: 2024 report of the Lancet standing
- 730 Commission. Lancet. 404, 572-628. https://doi.org/10.1016/S0140-6736(24)01296-0
- 731
- Loskutova, N., Honea, R., Brooks, W., Burns, J., 2010. Reduced limbic and hypothalamic
- volumes correlate with bone density in early Alzheimer's disease. J Alzheimers. Dis. 20, 313-
- 734 322. https://doi.org/10.3233/JAD-2010-1364
- 735
- T36 Lucey, B.P., Liu, H., Toedebusch, C.D., Freund, D., Redrick, T., Chahin, S.L., Mawuenyega,
- K.G., Bollinger, J.G., Ovod, V., Barthélemy, N.R., Bateman, R.J., 2023. Suvorexant acutely
- decreases tau phosphorylation and A $\beta$  in the human CNS. Ann. Neurol. 94, 27–40.
- 739 https://doi.org/10.1002/ana.26641
- 740

- 741 Nerattini, M., Rubino, F., Jett, S., Andy, C., Boneu, C., Zarate, C., Carlton, C., Loeb-Zeitlin,
- 742 S., Havryliuk, Y., Pahlajani, S., Williams, S., Berti, V., Christos, P., Fink, M., Dyke, J.P.,
- 743 Brinton, R.D., Mosconi, L., 2023. Elevated gonadotropin levels are associated with increased
- biomarker risk of Alzheimer's disease in midlife women. Front. Dement. 2, 1303256.
- 745 https://doi.org/10.3389/frdem.2023.1303256
- 746
- Nestor, P.J., Fryer, T.D., Smielewski, P., Hodges, J.R., 2003. Limbic hypometabolism in
- Alzheimer's disease and mild cognitive impairment. Ann. Neurol. 54, 343–351.
- 749 https://doi.org/10.1002/ana.10669
- 750
- 751 Niwczyk, O., Grymowicz, M., Szczęsnowicz, A., Hajbos, M., Kostrzak, A., Budzik, M.,
- 752 Maciejewska-Jeske, M., Bala, G., Smolarczyk, R., Męczekalski, B., 2023. Bones and
- hormones: interaction between hormones of the hypothalamus, pituitary, adipose tissue and
- 754 bone. Int. J. Mol. Sci. 24, 6840. https://doi.org/10.3390/ijms24076840
- 755
- O'Brien, J., Ames, D., Schweitzer, I., Colman, P., Desmond, P., Tress, B., 1996. Clinical and
- 757 magnetic resonance imaging correlates of hypothalamic-pituitary-adrenal axis function in
- depression and Alzheimer's disease. Br. J. Psychiatry. 168, 679-687.
- 759 https://doi.org/10.1192/bjp.168.6.679
- 760
- 761 Ofori, E., Solis, A., Punjani, N., 2024. The association among hypothalamic subnits,
- gonadotropic and sex hormone plasmas levels in Alzheimer's disease. Brain Sci. 14, 276.
- 763 https://doi.org/10.3390/brainsci14030276
- 764
- 765 Page, M.J., McKenzie, J.E., Bossuyt, P.M., Boutron, I., Hoffmann, T.C., Mulrow, C.D.,
- 766 Shamseer, L., Tetzlaff, J.M., Akl, E.A., Brennan, S.E., Chou, R., Glanville, J., Grimshaw,
- J.M., Hróbjartsson, A., Lalu, M.M., Li, T., Loder, E.W., Mayo-Wilson, E., McDonald, S.,
- 768 McGuinness, L.A., Stewart, L.A., Thomas, J., Tricco, A.C., Welch, V.A., Whiting, P., Moher,
- 769 D., 2021. The PRISMA 2020 statement: an updated guideline for reporting systematic
- 770 reviews. BMJ. 372, n71. https://doi.org/10.1136/bmj.n71
- 771
- Piguet, O., Petersén, A., Yin Ka Lam, B., Gabery, S., Murphy, K., Hodges, J.R., Halliday,
- 773 G.M., 2011. Eating and hypothalamus changes in behavioral-variant frontotemporal
- 774 dementia. Ann. Neurol. 69, 312–319. https://doi.org/10.1002/ana.22244
- 775
- Popp, J., Wolfsgruber, S., Heuser, I., Peters, O., Hüll, M., Schröder, J., Möller, H.-J.,
- Lewczuk, P., Schneider, A., Jahn, H., Luckhaus, C., Perneczky, R., Frölich, L., Wagner, M.,

778	Maier, W., Wiltfang, J., Kornhuber, J., Jessen, F., 2015. Cerebrospinal fluid cortisol and
779	clinical disease progression in MCI and dementia of Alzheimer's type. Neurobiol. Aging. 36,
780	601–607. https://doi.org/10.1016/j.neurobiolaging.2014.10.031
781	
782	Purba, J.S., Hofman, M.A., Swaab, D.F., 1994. Decreased number of oxytocin-
783	immunoreactive neurons in the paraventricular nucleus of the hypothalamus in Parkinson's
784	disease. Neurology. 44, 84–89. https://doi.org/10.1212/wnl.44.1.84
785	
786	Raadsheer, F.C., van Heerikhuize, J.J., Lucassen, P.J., Hoogendijk, W.J., Tilders, F.J.,
787	Swaab, D.F., 1995. Corticotropin-releasing hormone mRNA levels in the paraventricular
788	nucleus of patients with Alzheimer's disease and depression. Am. J. Psychiatry. 152, 1372-
789	1376. https://doi.org/10.1176/ajp.152.9.1372
790	
791	Saper, C.B., German, D.C., 1987. Hypothalamic pathology in Alzheimer's disease. Neurosci.
792	Lett. 74, 364–370. https://doi.org/10.1016/0304-3940(87)90325-9
793	
794	Saper, C.B., Scammell, T.E., Lu, J., 2005. Hypothalamic regulation of sleep and circadian
795	rhythms. Nature. 437, 1257–1263. https://doi.org/10.1038/nature04284
796	
797	Schultz, C., Braak, H., Braak, E., 1996. A sex difference in neurodegeneration of the human
798	hypothalamus. Neurosci. Lett. 212, 103–106. https://doi.org/10.1016/0304-3940(96)12787-7
799	
800	Schultz, C., Ghebremedhin, E., Braak, E., Braak, H., 1999. Sex-dependent cytoskeletal
801	changes of the human hypothalamus develop independently of Alzheimer's disease. Exp.
802	Neurol. 160, 186–193. https://doi.org/10.1006/exnr.1999.7185
803	
804	Shan, L., Bossers, K., Unmehopa, U., Bao, AM., Swaab, D.F., 2012. Alterations in the
805	histaminergic system in Alzheimer's disease: a postmortem study. Neurobiol. Aging. 33,
806	2585–2598. https://doi.org/10.1016/j.neurobiolaging.2011.12.026
807	
808	Shapiro, N.L., Todd, E.G., Billot, B., Cash, D.M., Iglesias, J.E., Warren, J.D., Rohrer, J.D.,
809	Bocchetta, M., 2022. In vivo hypothalamic regional volumetry across the frontotemporal
810	dementia spectrum. Neuroimage. Clin. 35, 103084.
811	https://doi.org/10.1016/j.nicl.2022.103084
812	
813	Smith, M.A., Bowen, R.L., Nguyen, R.Q., Perry, G., Atwood, C.S., Rimm, A.A., 2018.
Q1/	Putative appadetropin releasing hormone against therapy and demontia: an application of

814 Putative gonadotropin-releasing hormone agonist therapy and dementia: an application of

815 Medicare hospitalization claims data. J. Alzheimers. Dis. 63, 1269–1277.

816 https://doi.org/10.3233/JAD-170847

817

Soneson, C., Fontes, M., Zhou, Y., Denisov, V., Paulsen, J.S., Kirik, D., Petersén, A.,

- 819 Huntington Study Group PREDICT-HD investigators, 2010. Early changes in the
- 820 hypothalamic region in prodromal Huntington disease revealed by MRI analysis. Neurobiol.
- 821 Dis. 40, 531–543. https://doi.org/10.1016/j.nbd.2010.07.013
- 822

Soysal, P., Tan, S.G., Rogowska, M., Jawad, S., Smith, L., Veronese, N., Tsiptsios, D.,

824 Tsamakis, K., Stewart, R., Mueller, C., 2021. Weight loss in Alzheimer's disease, vascular

- 825 dementia and dementia with Lewy bodies: impact on mortality and hospitalization by
- dementia subtype. Int. J. Geriatr. Psychiatry. 37. https://doi.org/10.1002/gps.5659
- 827

Tang, X., Song, Z.-H., Wang, D., Yang, J., Augusto Cardoso, M., Zhou, J.-B., Simó, R., 2021.

- 829 Spectrum of thyroid dysfunction and dementia: a dose-response meta-analysis of 344,248
- individuals from cohort studies. Endocr. Connect. 10, 410–421. https://doi.org/10.1530/EC21-0047
- 832

Toledo, J.B., Toledo, E., Weiner, M.W., Jack, C.R., Jagust, W., Lee, V.M.Y., Shaw, L.M.,

- Trojanowski, J.Q., Alzheimer's Disease Neuroimaging Initiative, 2012. Cardiovascular risk
- 835 factors, cortisol, and amyloid- $\beta$  deposition in Alzheimer's disease neuroimaging initiative.
- 836 Alzheimers. Dement. 8, 483–489. https://doi.org/10.1016/j.jalz.2011.08.008
- 837

Tse, N.Y., Bocchetta, M., Todd, E.G., Devenney, E.M., Tu, S., Caga, J., Hodges, J.R.,

- Halliday, G.M., Irish, M., Kiernan, M.C., Piguet, O., Rohrer, J.D., Ahmed, R.M., 2023. Distinct
- 840 hypothalamic involvement in the amyotrophic lateral sclerosis-frontotemporal dementia
- 841 spectrum. Neuroimage. Clin. 37, 103281. https://doi.org/10.1016/j.nicl.2022.103281
- 842


Wells, G., Shea, B., O'Connell, D., Peterson, J., Welch, V., Losos, M., Tugwell, P., 2021. The
Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-

- 845 analyses. https://www.ohri.ca/programs/clinical\_epidemiology/oxford.asp (accessed 3rd Sept
- 846 847


2024).

- 848 Westwood, A.J., Beiser, A., DeCarli, C., Harris, T.B., Chen, T.C., He, X., Roubenoff, R.,
- Pikula, A., Au, R., Braverman, L.E., Wolf, P.A., Vasan, R.S., Seshadri, S., 2014. Insulin-like
- growth factor-1 and risk of Alzheimer dementia and brain atrophy. Neurology. 82, 1613–
- 851 1619. https://doi.org/10.1212/WNL.00000000000382

#### 852 853 Whitwell, J.L., Weigand, S.D., Shiung, M.M., Boeve, B.F., Ferman, T.J., Smith, G.E., 854 Knopman, D.S., Petersen, R.C., Benarroch, E.E., Josephs, K.A., Jack, C.R., Jr, 2007. Focal 855 atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease. 856 Brain. 130, 708–719. https://doi.org/10.1093/brain/awl388 857 858 Woolley, J.D., Khan, B.K., Natesan, A., Karydas, A., Dallman, M., Havel, P., Miller, B.L., 859 Rankin, K.P., 2014. Satiety-related hormonal dysregulation in behavioral variant 860 frontotemporal dementia. Neurology. 82, 512–520. 861 https://doi.org/10.1212/WNL.000000000000106 862 863 Xie, C., Wang, C., Luo, H., 2023. Increased risk of osteoporosis in patients with cognitive 864 impairment: a systematic review and meta-analysis. BMC. Geriatr. 23, 1–10. 865 https://doi.org/10.1186/s12877-023-04548-z 866 867 Yasui, K., Inoue, Y., Kanbayashi, T., Nomura, T., Kusumi, M., Nakashima, K., 2006. CSF 868 orexin levels of Parkinson's disease, dementia with Lewy bodies, progressive supranuclear 869 palsy and corticobasal degeneration. J. Neurol. Sci. 250, 120–123. 870 https://doi.org/10.1016/j.jns.2006.08.004 871 872 Yong-Hong, L., Xiao-Dong, P., Chang-Quan, H., Bo, Y., Qing-Xiu, L., 2013. Hypothalamic-873 pituitary-thyroid axis in patients with Alzheimer disease (AD). J. Investig. Med. 61, 578–581. 874 https://doi.org/10.2310/JIM.0b013e318280aafb 875 876 Zhou, H.-H., Yu, Z., Luo, L., Xie, F., Wang, Y., Wan, Z., 2021. The effect of hormone 877 replacement therapy on cognitive function in healthy postmenopausal women: a meta-878 analysis of 23 randomized controlled trials. Psychogeriatrics. 21, 926-938. 879 https://doi.org/10.1111/psyg.12768



**Figure 1.** Flowchart showing the selection of articles for the meta-analysis and secondary narrative synthesis. PET = positron emission tomography, SPECT = single-photon emission computed tomography.



**Figure 2.** Forest plot of the pooled standardised mean difference (Hedges' g) showing that subjects with Alzheimer's disease (AD) had a significantly smaller hypothalamus compared to healthy controls.




Figure 3. Funnel plot of included studies demonstrating no suggestion of publication bias.

**Table 1.** Summary of studies included in the data synthesis. ACE-R = Addenbrooke's cognitive examination revised, AD = Alzheimer's disease, Ant-Inf = anterior-inferior subunit, Ant-Sup = anterior-superior subunit, APEHQ = Appetite and eating habits questionnaire, BMI = body mass index, CBI = Cambridge behavioural inventory, DLB = dementia with Lewy bodies, FSH = follicle-stimulating hormone, Inf-Tub = inferior-tubular subunit, LH = lutenising hormone, M = mini-mental state examination, 3MS = modified mini-mental state examination, MPRAGE = magnetization prepared rapid gradient echo, NS = not significant, OSHy-X = open source hypothalamic-fornix atlas and tool, Post – posterior subunit, RBDSQ-K = Rapid eye movement behaviour disorder screening questionnaire Korean, ROIs = region of interests, SD = standard deviation, SPGR = spoiled gradient echo, Sup-Tub = superior-tubular subunit, T = Tesla, TIV = total intracranial volume, VBM = voxel based morphometry, %W = % women.

Study	Demographics	MRI characteristics	Risk of	Hypothalamic volume	Mean difference AD	Clinical correlations
Author	Group (n)	Field strength	bias	Mean (SD)	compared to controls	
(year)	Age, %W	Sequence			(%)	
	Cognition: M, 3MS, or ACE-R	Voxel or slice size				
		Analysis method				
Grundman	<u>AD (58)</u>	1.5T	Low	AD	-29.41%	BMI: r=0.14 (NS)
(1996)	71.8y, 50%W, M:19.2	Multiple-echo sequence.		0.12% (0.05%) of TIV		
		Slices: 5mm.				
	Controls (16)	Manual ROIs.		<u>Controls</u>		
	72.5y, 69%W, M:28.9			0.17% (0.04%) of TIV		
Baron	<u>AD (19)</u>	1.5T	Moderate	Gray matter loss in anterior	Not measured.	Not measured.
(2001)	73y, 58%W, M: 22.4	T1 (SPGR) sequence		hypothalamus in AD		
		Voxels: 2mm <sup>3</sup>		compared to controls.		
	Controls (16)	VBM				
	66y, 56%W, M not reported					
Callen	AD (40)	1.5T	Low	AD	-10.75%	Not measured
(2001)	69.1y, 50%W, M:19.5	T1 sequence.		266.5 (54.3) mm <sup>3</sup>		
. ,		Voxels: 0.634 mm <sup>3</sup> .				
	Controls (40)	Manual ROIs.		<u>Controls</u>		
	70.4y, 50%W, M:28.5			298.6 (43.2) mm <sup>3</sup>		
Callen	Same as Callen (2001).	Same as Callen (2001).	Low	Same as Callen (2001).	Same as Callen (2001).	Sex (men <women)< td=""></women)<>
(2004)						
Whitwell	AD (73)	1.5T	Low	Grey matter loss in the	Not measured.	Not measured.
(2007)	76y, 24%W, M:21	T1 (SPGR) sequence		hypothalamus in DLB		
		Slices: 1.6mm		compared to controls.		
	<u>DLB (73)</u>	VBM	1			
	73y, 24%W, M:22					
	Controls (73)					
	74y, 24%W, M:29					
Hall	AD (26)	1.5T	Moderate	Croy mottor loss in the	Not measured.	Not measured.
(2008)		T1 (SPGR) sequence	Moderate	Grey matter loss in the hypothalamus in AD	not measured.	not measured.
(2008)	83.2y, 61%W, 3MS:76.7	Voxels: 1 mm <sup>3</sup>	1	compared to controls, and		
	Controlo (127)	VOXets: 1 mm <sup>-</sup>		in subjects who later		
	<u>Controls (127)</u>	VDIN		-		
	77.3y, 54%W, 3MS:96.9		1	developed AD.		

#### Table 1 continued.

<b>Study</b> Author (year)	Demographics Group (n) Age, %W Cognition: M or ACE-R	MRI characteristics Field strength Sequence Voxel or slice size Analysis method	Risk of bias	Hypothalamic volume Mean (SD)	Mean difference AD compared to controls (%)	Clinical correlations
Loskutova (2010)	AD (63) 74.4y, 62%W, M:26.1 <u>Controls (55)</u> 73.2y, 58%W, M:29.5	3T T1 (MPRAGE) sequence Voxels:1 mm <sup>3</sup> . VBM with small volume correction.	Moderate	AD 570 (100) mm <sup>3</sup> <u>Controls</u> 650 (120) mm <sup>3</sup>	-12.31%	Bone mineral density: r = 0.34, (p = 0.007)
Ahmed (2015)	AD (30) 68y, 27%W, ACE-R: 68 <u>Controls (23)</u> 72y, 52%W, ACE-R: 94	Field strength not stated. T1 sequence Voxels: 1 mm <sup>3</sup> . Manual ROIs.	Moderate	AD 0.138% (0.02%) of TIV. <u>Controls</u> 0.137% (0.013%) of TIV	+0.73%	CBI (NS), APEHQ (NS) BMI (NS) Leptin (NS) Cholecystokinin (NS) Peptide YY (NS) Oxytocin (NS) Ghrelin (NS) Agouti-related peptide (NS)
Kim (2016)	AD (23) 71.6y, 61%W, M:20,1 <u>Controls (36)</u> 72.9y, 47%W, M:29.3	3T T1 (SPGR) sequence. Slices: 1mm. VBM	Low	Not reported.	Not reported.	RBDSQ-K score (trend only).
Billot (2020)	AD (134) 76.0y, 46%W Controls (183) 72.9y, 49%W M not reported.	T1 Sequence not reported. Voxels: 1mm <sup>3</sup> . Automated segmentation using Freesurfer.	High	Not reported.	<u>Cohen's d</u> Hypothalamus (0.96) Ant-Sup (1.16) Ant-Inf (0.99) Sup-Tub (0.60) Inf-Tub (0.34) Post (0.94)	Not reported.
Chang (2022)	AD (167) 68y, 50%W <u>Controls (527)</u> 68y, 58%W M not reported	3T or 7T T1 (MPRAGE or accelerated inversion recovery SPGR) sequence Voxels: 1mm <sup>3</sup> or 0.9 mm <sup>3</sup> . Automated segmentation using OSHy-X.	High	AD 746.62 mm3 (121.29) <u>Controls</u> 771.2 mm3 (97.88)	-3.19%	BMI (NS) Sex (NS)
Ofori (2024)	AD (96) 75.1y, 45%W, M:21.3 <u>Controls (54)</u> 75.3y, 48%W, M:29.1	1.5T T1 (MPRAGE) sequence. Automatic segmentation using Freesurfer.	Moderate	AD 0.034% (0.0039%) <u>Controls</u> 0.036% (0.0037%)	-5.56%	Sex (men <women) In women only: FSH and Inf-Tub. (R<sup>2</sup>=0.11) LH and Inf-Tub. (R<sup>2</sup>=0.11) Testosterone (NS) Progesterone (NS)</women) 